Antiviral treatment standards for hepatitis B: An urgent need for expansion

doi:10.3748/wjg.v30.i4.418

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1559)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

WORD

HTML

941

Sum=1014

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

180

Download

276

Sum=456

Jan 28, 2024 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Jan 28, 2024; 30(4): 418-420
Published online Jan 28, 2024. doi: 10.3748/wjg.v30.i4.418

Antiviral treatment standards for hepatitis B: An urgent need for expansion

Zi-Hong Bao, Zhi-Kun Dai, Hao-Xian Tang

Zi-Hong Bao, Zhi-Kun Dai, Department of Infectious Diseases, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China

Hao-Xian Tang, Medical College, Shantou University Medical College, Shantou 515041, Guangdong Province, China

Hao-Xian Tang, Department of Cardiology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China

Co-first authors: Zi-Hong Bao and Zhi-Kun Dai.

Author contributions: Bao ZH and Dai ZK contributed equally to the manuscript; Tang HX designed research; Bao ZH and Dai ZK performed research; Bao ZH and Dai ZK wrote the letter; Tang HX revised the letter; All authors approved the final version of the article.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Hao-Xian Tang, MD, Doctor, Medical College, Shantou University Medical College, No. 22 Xinling Road, Jinping District, Shantou 515041, Guangdong Province, China. 19hxtang@stu.edu.cn

Received: September 27, 2023
Peer-review started: September 27, 2023
First decision: December 4, 2023
Revised: December 16, 2023
Accepted: January 8, 2024
Article in press: January 8, 2024
Published online: January 28, 2024
Processing time: 120 Days and 16 Hours

Core Tip

Core Tip: Chronic hepatitis B (CHB) is a serious public health problem. Early detection and effective antiviral treatment can remarkably reduce liver-related mortality caused by CHB. However, the global diagnosis and treatment rates of CHB are only 10% and 2%, respectively. Expanding the standard of antiviral treatment for patients with hepatitis B is urgently needed to improve cost-effectiveness and survival further.